Page last updated: 2024-09-03

imatinib mesylate and Cutaneous Mastocytosis

imatinib mesylate has been researched along with Cutaneous Mastocytosis in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (16.67)	29.6817
2010's	3 (50.00)	24.3611
2020's	2 (33.33)	2.80

Authors

Authors	Studies
Álvarez-Twose, I; Giacaman, A; Guibelalde, M; Martín-Santiago, A; Salinas Sanz, JA	1
Bartram, J; Kendall, J; Martinez, A	1
Falchi, L; Verstovsek, S	1
Agarwala, MK; Balasubramanian, P; George, R; Mathews, V; Nair, S; Thomas, M	1
Benesch, M; Binder, B; Hoffmann, KM; Lackner, H; Lohse, P; Moser, A; Schwinger, W; Sovinz, P; Urban, C; Winkler, A	1
Debiec Rychter, M; Dubreuil, P; Hoppé, A; Martin, L; Morren, MA; Renard, M; Uyttebroeck, A	1

Reviews

1 review(s) available for imatinib mesylate and Cutaneous Mastocytosis

Article	Year
Kit Mutations: New Insights and Diagnostic Value. Immunology and allergy clinics of North America, 2018, Volume: 38, Issue:3 Topics: Humans; Imatinib Mesylate; Mast Cells; Mastocytosis, Cutaneous; Mastocytosis, Systemic; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Skin; Staurosporine	2018

Other Studies

5 other study(ies) available for imatinib mesylate and Cutaneous Mastocytosis

Article	Year
Diffuse cutaneous mastocytosis in a girl with M541L polymorphism in KIT gene: Response to treatment with imatinib. Anales de pediatria, 2023, Volume: 99, Issue:5 Topics: Female; Humans; Imatinib Mesylate; Mastocytosis, Cutaneous; Polymorphism, Genetic	2023
Imatinib for control of bullous skin lesions in a child with familial mastocytosis. British journal of haematology, 2021, Volume: 194, Issue:6 Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Infant; Male; Mastocytosis, Cutaneous; Skin	2021
Role of imatinib in the treatment of pediatric onset indolent systemic mastocytosis: a case report. The Journal of dermatological treatment, 2013, Volume: 24, Issue:6 Topics: Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Mastocytosis, Cutaneous; Mastocytosis, Systemic; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Urticaria Pigmentosa; Young Adult	2013
Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation. Blood, 2008, Sep-01, Volume: 112, Issue:5 Topics: Amino Acid Substitution; Antineoplastic Agents; Benzamides; Child, Preschool; Germ-Line Mutation; Humans; Imatinib Mesylate; Infant; Male; Mastocytosis, Cutaneous; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Sequence Deletion	2008
Imatinib mesylate in the treatment of diffuse cutaneous mastocytosis. The Journal of pediatrics, 2013, Volume: 162, Issue:1 Topics: Benzamides; Female; Humans; Imatinib Mesylate; Infant; Mastocytosis, Cutaneous; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2013